Tranquis Therapeutics, a trailblazing clinical-stage biopharmaceutical company, is developing a portfolio of small molecule drugs capable of reprogramming dysfunctional myeloid immune cells to restore normal cell homeostasis and function.
Our therapeutic candidates can “switch” dysfunctional microglia and monocytes back to a more functional state by targeting master regulators of cell energy metabolism, such as PGC1α. We have the potential to revolutionize the management of an entire range of CNS and non-CNS indications by modifying disease—starting with ALS—to improve millions of lives throughout the world.
Join our exciting, collaborative and passionate
workplace—driven to make a difference in patients’ lives